Intestinal Research

IBD
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease: Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2023;21(1):43-60. Published online October 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00029
Web of Science 13 Crossref 15; Full text PubReader ePub PDF

Inflammatory bowel diseases
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases: Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus, Jr; Intest Res. 2020;18(1):34-44. Published online January 30, 2020; DOI: https://doi.org/10.5217/ir.2019.09147
Web of Science 19 Crossref 17; Full text PubReader ePub PDF

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice: Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2019;17(4):504-515. Published online August 23, 2019; DOI: https://doi.org/10.5217/ir.2019.00030
Web of Science 13 Crossref 14; Full text PubReader ePub PDF

WITHDRAWN:Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members: Soo-Kyung Park, Tadakazu Hisamatsu, Zhihua Ran, Shu-Chen Wei, Dong Il Park; Received June 12, 2018 Accepted October 6, 2018; DOI: https://doi.org/10.5217/ir.2018.00084
Crossref 1

IBD
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis: Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood; Intest Res. 2018;16(1):83-89. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.83
Crossref 11; Full text PubReader ePub PDF

Current status of biosimilars in the treatment of inflammatory bowel diseases: Dong Il Park; Intest Res. 2016;14(1):15-20. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.15
Web of Science 15 Crossref 15; Full text PubReader ePub PDF

Search